TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
TScan Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $97.03M, down 17.8% year over year. For fiscal 2025 it was $114.15M, up 6.3% from the year before. The highest annual figure on record is $114.15M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.15M | +6.3% |
| FY2024 | Dec 31, 2024 | $107.35M | +21.8% |
| FY2023 | Dec 31, 2023 | $88.15M | +47.4% |
| FY2022 | Dec 31, 2022 | $59.82M | +33.1% |
| FY2021 | Dec 31, 2021 | $44.95M | +118.5% |
| FY2020 | Dec 31, 2020 | $20.58M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $23.40M | -28.3% |
| Q1 FY2026 | Mar 31, 2026 | $21.90M | -26.5% |
| Q4 FY2025 | Dec 31, 2025 | $20.04M | -31.7% |
| Q3 FY2025 | Sep 30, 2025 | $31.69M | +20.7% |
| Q2 FY2025 | Jun 30, 2025 | $32.63M | +21.4% |
| Q1 FY2025 | Mar 31, 2025 | $29.79M | +19.8% |
| Q4 FY2024 | Dec 31, 2024 | $29.35M | +31.0% |
| Q3 FY2024 | Sep 30, 2024 | $26.26M | +15.5% |
| Q2 FY2024 | Jun 30, 2024 | $26.88M | +26.6% |
| Q1 FY2024 | Mar 31, 2024 | $24.86M | +14.1% |
| Q4 FY2023 | Dec 31, 2023 | $22.41M | +43.6% |
| Q3 FY2023 | Sep 30, 2023 | $22.74M | +51.3% |
| Q2 FY2023 | Jun 30, 2023 | $21.23M | +46.5% |
| Q1 FY2023 | Mar 31, 2023 | $21.78M | +48.3% |
| Q4 FY2022 | Dec 31, 2022 | $15.60M | +23.8% |
| Q3 FY2022 | Sep 30, 2022 | $15.03M | +5.8% |
| Q2 FY2022 | Jun 30, 2022 | $14.49M | +34.2% |
| Q1 FY2022 | Mar 31, 2022 | $14.69M | +100.2% |
| Q4 FY2021 | Dec 31, 2021 | $12.61M | +111.4% |
| Q3 FY2021 | Sep 30, 2021 | $14.21M | +144.4% |
| Q2 FY2021 | Jun 30, 2021 | $10.80M | +139.9% |
| Q1 FY2021 | Mar 31, 2021 | $7.34M | – |
| Q4 FY2020 | Dec 31, 2020 | $5.96M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.81M | – |
| Q2 FY2020 | Jun 30, 2020 | $4.50M | – |
See a number that looks wrong?